Atlas Trials

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

Clinical trial NCT06478212 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06478212
Sponsor
Institut de Recherches Internationales Servier
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
IDH1-mutant GliomaIDH2-mutant Glioma
Start date
2025-01-22
Primary completion
2027-11-01
Enrollment
51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.